Capital Wealth
TUE CLOSE · SEP 15   S&P 500 7,585.73 ▼0.45%  ·  DJIA 52,093.11 ▼0.63%  ·  NASDAQ 25,981.57 ▼0.78%  ·  10-YR 4.996%  ·  2-YR 4.673%  ·  WTI $106.05 ▲4.6%  ·  GOLD $4,337.00 ▼0.3%  ·  VIX 17.42 ▲1.9%
Business & Finance · Pharma

Pfizer’s Unusual Way to Collect on Unwanted Covid Shots: Air-Traffic Control Fees

Poland and Romania balked at vaccine deals they no longer needed. Pfizer won in court, then went after the fees airlines pay to cross their skies.

By Sean Anees Saifi · Capital Wealth · Published Tuesday, September 15, 2026 · Source: The Wall Street Journal, September 14, 2026 edition (Business & Finance)
Key Points
$2.2B
what Pfizer seeks for unwanted Covid-19 vaccines
80%+
Polish agency’s budget the frozen fees normally cover
20%
salary cut for Romatsa’s 1,700 staff
90M+
shots Poland and Romania were held to
An empty air traffic control console with a headset, paper cup and chair overlooking airport runway lights at dusk.
Airlines pay fees to fly over Poland and Romania, and Pfizer has a court-approved lien on that money. Both countries’ air-navigation agencies say the move puts air safety at risk.
In one line: To collect $2.2 billion for unwanted Covid-19 vaccines, Pfizer put a lien on the airspace fees that pay Poland’s and Romania’s air-traffic controllers.

Most bill collectors phone your house. Pfizer (PFE) looked up. Poland and Romania owe the drugmaker $2.2 billion for unwanted Covid-19 vaccines. To collect, it won court approval in July for a lien — a legal claim on money until a debt is paid — on fees airlines pay to cross those countries’ skies. That’s the money that pays their air-traffic controllers.

Who owes whom, and why

It starts in 2021. Negotiating for all 27 member states, the European Union locked in hundreds of millions of Covid-19 doses in a landmark deal. Pfizer, which developed the shot with BioNTech (BNTX), committed to making and delivering it locally. Signed at the height of the scramble for shots, the deal left Europe with far more doses than it needed.

Other EU countries settled their way out. Poland and Romania didn’t. In early 2022, Poland said it could no longer afford 63 million more doses, and Romania soon followed. In April, Pfizer won a yearslong legal fight holding both to deals for more than 90 million shots. From Poland it’s pursuing €1.3 billion, roughly $1.5 billion, a sum the health minister compared to the country’s yearly spending on cancer drugs. Romania owes another €600 million.

Follow the airline money

Here’s the plumbing. Airlines pay fees to fly through a country’s airspace. In the U.S., they pay the Federal Aviation Administration directly. In Europe, a regional body called Eurocontrol collects the fees and passes them along to each country. Pfizer’s lien freezes Poland’s and Romania’s cut. For Pansa, Poland’s air-navigation agency, that money is more than 80% of the budget, says its chief executive, Magdalena Jaworska-Maćkowiak.

The strain shows. Pansa got emergency government funding less than 24 hours before it would have run out of cash, she says. Romania’s agency, Romatsa, cut salaries 20% for its 1,700 staff before winning a reprieve last month. Both agencies say Pfizer is putting air safety at risk. “I’m here for air-traffic management, not for fighting with Pfizer,” Jaworska-Maćkowiak said.

Pfizer calls its moves a measured way to uphold its contract, and says the court’s ruling shows how much Europe’s pandemic response relied on contracts being honored. Eurocontrol recently won protections against liens like these, but they didn’t take effect until Aug. 9, too late for this case. Both countries have appealed, with hearings set for October and January.

What It Means For Your Portfolio

Hold — no portfolio change from this fight

Hold: nothing in the portfolios changes, but the fight is a sharp reminder that a contract signed in a scramble can outlast the need that inspired it.

The general planning principle here isn’t advice for anyone in particular, and it starts with opportunity cost — what else the same money could have done. Poland’s health minister measured this bill against a year of cancer-drug spending. Read the exit terms before you sign, especially when everyone’s in a hurry. If you want out later, negotiating early can cost less than a yearslong fight.

Pfizer isn’t held in the Capital Wealth portfolios, and nothing in them changes because of this story. We’re cautious and neutral on stocks, and nothing new gets bought ahead of Wednesday’s Fed decision. The household move: before signing any long contract, find the exit clause. Exit clauses and umbrellas share a rule: they’re worth locating long before the clouds gather. Give a review fifteen minutes, and bring one statement.

Book a 15-Minute Review → Back to Edition No. 170 →